Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Inflammatory, and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD31/PECAM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD31/PECAM1 ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD31 Products |
| Gene Delivery | CD31/PECAM1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction in adhesion assays. |
View CD31 Products |
| Benchmark Ab | Anti-CD31 Recombinant Antibody Recombinant positive control for validation assays. |
View CD31 Products |
| Validator | CD31/PECAM1 siRNA Set For knockdown verification in endothelial cell assays. |
View CD31 Products |
| Related Target A | CD146 (MCAM) Synergistic endothelial cell junction molecule involved in angiogenesis and vascular permeability. |
View CD146 Products |
| Related Target B | VE-Cadherin (CD144) Co-regulator of endothelial cell-cell junctions and vascular barrier integrity. |
View VE-Cadherin Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homophilic Interaction Interference | HEK293-expressed CD31 ECD-Fc preserves native dimeric conformation required for homophilic binding screening. |
| Cross-species Transendothelial Migration (TEM) Modeling | Human, Cynomolgus, and Mouse ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Recombinant Controls | Sequence-verified clinical biosimilar antibodies included for assay standardization. |
| Off-Target Endothelial Toxicity | Endotoxin-controlled formulations (<1.0 EU/μg) prevent non-specific immune activation in primary cell assays. |
Live CD31/PECAM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD31 (PECAM1) is rapidly diversifying. Long recognized as a biomarker for endothelial cells and vascular density, CD31 is increasingly targeted as a functional modulator in transendothelial migration (TEM), vascular barrier integrity, and platelet aggregation. The translational focus has expanded from cardiovascular disease and thrombosis to oncology (inhibiting tumor angiogenesis) and autoimmune disorders (restoring blood-brain barrier/vascular wall stability). As therapeutic strategies transition from simple blocking antibodies to bispecific constructs and targeted cell therapies, precise reagents that preserve native glycosylation and structural conformations are essential for clinical translation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Blocking) | Academic/Biotech Consortiums | Inflammatory Diseases, Thrombosis | Homophilic interaction blocking assays (Requires high-purity ECD-Fc) |
| Agonistic Antibodies / Peptides | Cardiovascular Research Institutes | Atherosclerosis, Myocardial Infarction | Endothelial cell barrier protection assays (Requires native HEK293 glycosylation) |
| Bispecific Antibodies (CD31 x Ang2) | Oncology Biopharma | Solid Tumors (Anti-angiogenesis) | Dual-targeting binding affinity validation (Requires sequence-verified orthologs) |